GLP-1 & compounded medication availability in Oregon (2026)

Oregon’s pharmacy regulator took the unusual step of publishing a formal, versioned position statement on compounded semaglutide, one that reads less like a warning and more like a specification: when compounding is permitted, and exactly how the ingredient must be sourced. Here is what ships to Oregon addresses across all ten product lines we track, with that document cited below.

Conditional state

Availability facts last reviewed: November 16, 2026

What ships to Oregon: all ten lines

Availability of all ten OrderlyMeds product lines in Oregon, with typical delivery times and notes
Product lineAvailable in Oregon?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Ships under a patient-specific prescription; sourcing rules below.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days Flat national price at every dose.
NAD+ Yes 8–10 business days Ships from licensed partner pharmacies.
Sermorelin Yes 8–10 business days Longevity family; same ordering flow.
Glutathione No N/A Not part of the OrderlyMeds formulary right now.
BPC-157 Yes 8–10 business days Compounded injectable; federal status below.
TB-500 Yes 8–10 business days Compounded injectable. Its section is below.
KPV No N/A Not carried; we compound peptide lines as injectables only.
Epitalon Yes 8–10 business days Compounded injectable; see the federal picture below.
MOTS-c Yes 8–10 business days Compounded injectable with its own federal record, below.

Where the answer is “No,” we say so instead of hiding the row. Oregon facts on this page were last reviewed on November 16, 2026.

Research peptides in Oregon: BPC-157, TB-500, KPV, Epitalon & MOTS-c

BPC-157, TB-500, Epitalon and MOTS-c ship to Oregon addresses as compounded injectables under patient-specific prescriptions. KPV does not, because our peptide lines are compounded as injectables only. Oregon’s regulator cares intensely about ingredient sourcing (its position statement bars “research use only” material outright), which is one more reason each section below states that substance’s own federal record plainly, whether or not the line ships to you.

BPC-157 in Oregon

Ships to Oregon addresses as a compounded injectable, filled under a patient-specific prescription from pharmaceutical-grade ingredients. The two federal facts below apply in full.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Oregon

Available to Oregon addresses as a compounded injectable under a patient-specific prescription. Read its federal record below first.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Oregon

We do not ship KPV to Oregon or any other state. Our peptide lines are injectables, and KPV is not compounded that way for us.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Oregon

Part of our Oregon offering as a compounded injectable on a patient-specific prescription. The federal facts below are unchanged by geography.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Oregon

MOTS-c ships to Oregon addresses as a compounded injectable on a patient-specific prescription. Its federal record, below, differs from the four lines above it.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Oregon’s pharmacy regulators say about compounded medications

Oregon is one of the few states whose pharmacy regulator has committed its GLP-1 position to a formal, versioned document rather than a newsletter mention. The current version spells out when compounding is permitted at all and, in the part that matters most for mail-order patients, how the raw ingredient has to be sourced before a single vial is made. Nothing in it singles out the other lines on this page, and no Oregon-specific restriction applies to them beyond that framework.

The board’s Semaglutide Position Statement (v. 02/2025) states that the federal FD&C Act prohibits compounding drug products that are essentially copies of a commercially available drug product, and recognizes three situations in which a compounded drug is not such a copy: the drug has been discontinued and is no longer marketed; the drug is listed on FDA’s shortage list; or a specific formulation change serves an identified patient whose medical needs the commercially available product cannot meet, with the significant benefit produced by that change. Source: Oregon Board of Pharmacy — Semaglutide Position Statement v. 02/2025.

The same position statement sets the sourcing floor: any semaglutide API must be pharmaceutical grade, accompanied by a valid certificate of analysis, and sourced from an establishment registered with FDA under section 510 of the FD&C Act; “research use only” material may not be used for compounding in any circumstance; no salt form of semaglutide may be used; and compounding or dispensing that fails to conform with governing law may lead to enforcement action by the board. Source: Oregon Board of Pharmacy — Semaglutide Position Statement v. 02/2025.

Out-of-state pharmacies shipping prescriptions to Oregon patients must register with the board before dispensing into the state. Source: Oregon Board of Pharmacy.

Oregon permits prescribing on the basis of a telehealth evaluation that meets the standard of care; no in-person-first requirement applies to the medications on this page. Source: Center for Connected Health Policy (CCHP) Policy Finder.

For an Oregon patient, the practical consequence of the position statement is about quality, not access: a compliant pharmacy documents the patient-specific reason for compounding and sources pharmaceutical-grade ingredients with a certificate of analysis, which is the model OrderlyMeds’ partner pharmacies are built around. The ordering path is the usual one: eligibility check online, telehealth evaluation with an Oregon-licensed provider, fulfillment by a registered pharmacy. Pricing is the same in Oregon as everywhere else we ship.

Oregon availability FAQs

Is compounded semaglutide available in Oregon?

Yes. OrderlyMeds ships compounded semaglutide to Oregon addresses under a patient-specific prescription, from pharmacies that meet the sourcing bar the state’s position statement sets out. New customers start at $74/month for the first two months.

Does Oregon require an in-person visit before a telehealth prescription?

No. An evaluation by an Oregon-licensed provider over telehealth meets the state’s standard-of-care requirement, and the cited regulator section above has the detail.

Can I get BPC-157 or other research peptides shipped to Oregon?

Four of the five on this page do ship to Oregon: BPC-157, TB-500, Epitalon and MOTS-c, each as a compounded injectable under a patient-specific prescription. KPV does not. Every section above carries that substance’s own federal record, including FDA’s safety position.

How long does delivery to Oregon take?

Plan on 8–10 business days from signup. That is our published window for Oregon addresses.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone